| # | Drug | Count |
|---|---|---|
| 0 | ECULIZUMAB | 18 |
| 1 | MYCOPHENOLATE MOFETIL | 15 |
| 2 | MYCOPHENOLATE MOFETIL HYDROCHLORIDE | 15 |
| 3 | PREDNISONE | 12 |
| 4 | RAVULIZUMAB | 9 |
| 5 | HYDROXYCHLOROQUINE | 8 |
| 6 | BELIMUMAB | 6 |
| 7 | METHYLPREDNISOLONE | 6 |
| 8 | ADALIMUMAB | 5 |
| 9 | ADALIMUMAB-AATY | 5 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | IPTACOPAN | 1 | 0.0013 |
| 1 | PENICILLIN G SODIUM | 1 | 0.0009 |
| 2 | HYALURONIC ACID | 1 | 0.0009 |
| 3 | AMPICILLIN SODIUM AND SULBACTAM SODIUM | 2 | 0.0008 |
| 4 | POLYETHYLENE GLYCOL 3350, SODIUM SULFATE ANHYDROUS, SODIUM BICARBONATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE | 1 | 0.0008 |
| 5 | DOLUTEGRAVIR SODIUM AND LAMIVUDINE | 2 | 0.0006 |
| 6 | BASILIXIMAB | 5 | 0.0004 |
| 7 | ECULIZUMAB | 18 | 0.0003 |
| 8 | ALOGLIPTIN | 1 | 0.0003 |
| 9 | PYRIDOSTIGMINE BROMIDE ORAL | 1 | 0.0003 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Complement Inhibitor [EPC] | 26 | 0.0005 |
| 1 | Neonatal Fc Receptor Blocker [EPC] | 1 | 0.0002 |
| 2 | B Lymphocyte Stimulator-specific Inhibitor [EPC] | 6 | 0.0002 |
| 3 | Alkaloid [EPC] | 3 | 0.0001 |
| 4 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 7 | 0.0001 |
| 5 | Anticholinergic [EPC] | 1 | 0.0001 |
| 6 | Carbonic Anhydrase Inhibitor [EPC] | 1 | 0.0000 |
| 7 | Antimetabolite Immunosuppressant [EPC] | 1 | 0.0000 |
| 8 | Tetracycline-class Drug [EPC] | 3 | 0.0000 |
| 9 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 2 | 0.0000 |